Cardiovascular-kidney-metabolic syndrome and risk of all-cause and cause-specific mortality among cancer survivors: a population-based cohort study Authors: Yumeng Liu, Zhongguang Yang, Yulin Yin Published: 2026 ABSTRACT BackgroundCardiovascular-kidney-metabolic (CKM) syndrome reflects the interplay of metabolic dysfunction, chronic kidney disease (CKD), and cardiovascular disease (CVD). However, the prognostic implications of CKM syndrome stages in this population remain unclear.MethodsData were drawn from the fasting subsample of NHANES III (1988–1994) and NHANES 1999–2018. A total of 2598 cancer survivors aged ≥ 20 years were included. Cox proportional hazards models accounting for the complex survey design were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).ResultsDuring a median follow-up of 7.92 years (IQR: 4.00–12.58), 1165 all-cause deaths, 352 CCD deaths, and 350 cancer deaths occurred. In fully adjusted models, compared with Stage 0, Stage 4 was associated with 3.48-fold higher all-cause mortality (HR = 3.48; 95% CI 2.62–4.63), 7.77-fold higher CCD mortality (HR = 7.77; 95% CI 4.21–14.32), and 2.55-fold higher cancer mortality (HR = 2.55; 95% CI 1.52–4.28). Advanced CKM syndrome was associated with elevated risks of all-cause, and cancer mortality. Sensitivity analyses confirmed the robustness of these findings.ConclusionAdvanced CKM syndrome is independently associated with increased risk of all-cause, cardiovascular, and cancer mortality among U.S. cancer survivors.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13148-026-02178-x. Introduction Cardiovascular-Kidney-Metabolic (CKM) syndrome refers to the pathophysiological interplay among cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic disorders such as obesity, insulin resistance, and type 2 diabetes [1]. In 2023, the American Heart Association (AHA) formally recognized CKM syndrome as a progressive condition encompassing five distinct stages, from early risk to advanced multi-organ dysfunction, which was intended to facilitate early identification and stage-specific intervention [2]. The mechanism of CKM syndrome is complex, including hemodynamic disturbances, chronic low-grade inflammation, neurohormonal activation, and metabolic dysregulation [3]. Metabolic syndrome, a central metabolic phenotype within the CKM continuum, has been associated with worse cardiovascular outcomes and is thought to act, in part, through pro-inflammatory and oxidative stress pathways [4–6]. In the United States, over one in four adults exhibit at least one component of the CKM syndrome, and about 25–30% of individuals experience overlapping comorbidities related to CKM syndrome worldwide [7]. As the population continues to age, cancer survivors are increasingly older and burdened with multiple comorbidities. With the number of elderly cancer survivors projected to rise in the future, the effective management of comorbid conditions is becoming an increasingly critical component of survivorship care. By 2025, the population of cancer survivors in the United States had exceeded 18.6 million, and this number is expected to rise to over 22 million by 2035 [8]. Although this reflects significant progress in cancer detection and treatment, it also introduces new challenges related to long-term survivorship. Among these, chronic comorbidities are increasingly prevalent. Notably, CVD has become the leading cause of noncancer mortality in cancer survivors [9]. Increasing evidence also suggested that metabolic dysfunction and CKD also contribute significantly to poor long-term outcomes. Moreover, existing studies report that CKM-related conditions, including obesity, metabolic syndrome, diabetes, and CKM syndrome itself, affect approximately 25 to 40% of the general population [10]. In individuals with cancer, these prevalence rates are markedly higher, which reflect the convergence of shared risk factors and the metabolic toxicity induced by cancer therapies. Cancer survivors face an elevated risk of developing various chronic comorbidities, most notably hypertension, dyslipidemia, CKD, and diabetes. For example, nearly half of breast cancer survivors develop metabolic syndrome after treatment, especially with endocrine therapy [11]. And 20–25% of prostate cancer patients on androgen deprivation therapy (ADT) develop new-onset diabetes within five years [10]. As a result, cancer patients, particularly long-term survivors, are at significantly elevated risk for experiencing CKM syndrome. This vulnerability stems not only from shared traditional risk factors but also from the systemic toxicities induced by cancer therapies [12]. Meanwhile, several studies have shown that individual components of CKM syndrome was associated with increased risk of mortality among cancer survivor. A recent analysis using the National Health and Nutrition Examination Survey (NHANES) data identified a nonlinear relationship between hemoglobin A1c (HbA1c) and all-cause mortality in cancer survivors, with mortality risk increasing above an HbA1c threshold of 5.4% [13]. Similarly, central obesity has been identified as a strong predictor of adverse outcomes in this population [14]. Although individual components of CKM syndrome have been linked to poor prognosis in cancer survivors, it remains unclear whether more advanced stages of CKM syndrome, which is characterized by the co-occurrence of multiple chronic conditions and further increase the risk of adverse outcomes. Understanding the cumulative impact of CKM syndrome severity on long-term prognosis among cancer survivors is essential for developing integrated management strategies and improving survivorship care. However, the prognostic implications of CKM syndrome stages in cancer survivors remain poorly understood. Previous research has largely examined individual components in isolation, without accounting for the syndromic nature of CKM. To address this gap, this population-based cohort study used nationally representative NHANES data to evaluate the association between CKM syndrome stages and mortality among U.S. cancer survivors. The primary outcome was all-cause mortality, and the secondary outcomes were cardio-cerebrovascular disease (CCD) mortality and cancer-specific mortality. Materials and methods Study population Data were obtained from the NHANES, conducted by the National Center for Health Statistics (NCHS). NHANES employs a complex, multistage, stratified probability sampling design to generate nationally representative estimates for the non-institutionalized U.S. population. All participants provided written informed consent, and the survey protocols were approved by the NCHS Research Ethics Review Board. Detailed information on study design and data collection procedures is available at https://wwwn.cdc.gov/nchs/nhanes/. A total of 37,374 individuals from the fasting subsample of NHANES III (1988–1994) and NHANES 1999–2018 were initially considered. After excluding participants aged < 20 years (n = 7145), those without a self-reported cancer diagnosis (n = 27,620), pregnant individuals (n = 10), and those with missing follow-up data (n = 1), 2598 adult cancer survivors were included in the final analysis (Fig. 1). Fig. 1Flowchart illustrating the selection of participants from NHANES III (1988–1994) and NHANES 1999–2018 Flowchart illustrating the selection of participants from NHANES III (1988–1994) and NHANES 1999–2018 Assessment of CKM syndrome CKM syndrome stages were defined based on the 2023 AHA Presidential Advisory [2], with necessary adaptations to align with variables available in NHANES III (1988–1994) and NHANES 1999–2018 [11]. Participants were classified into five stages (0–4), representing a continuum of CKM-related risk. A detailed operational definition of each CKM stage, including the NHANES-derived cut-points and the adaptations applied to the AHA framework, is provided in Table S1. For subsequent analyses, advanced CKM syndrome was defined as Stage 3 or Stage 4, reflecting the presence of subclinical or clinical cardiovascular disease and/or very high-risk chronic kidney disease [11]. Assessment of cancer survivors Cancer survivors were defined as participants aged ≥ 20 years who answered “yes” to the question, “Have you ever been told by a doctor or other health professional that you had cancer or a malignancy of any kind?” Individuals reporting only non-melanoma skin cancer were excluded, consistent with previous epidemiological studies [15]. Information on cancer type, diagnosis date, and treatment history was not uniformly available and was therefore not considered in the classification. Assessment of mortality Mortality outcomes were captured via linkage to the National Death Index (NDI) through the NHANES Linked Mortality Files, with follow-up through December 31, 2019. The primary outcome was all-cause mortality. Cause-specific mortality was defined according to the underlying cause of death coded by ICD-10. Cardiovascular‑cerebrovascular disease (CCD) mortality was defined using ICD-10 codes I00–I99, which encompass both cardiovascular and cerebrovascular deaths, with cerebrovascular-specific codes I60–I69. Cancer mortality was identified using ICD-10 codes C00–C97 for malignant neoplasms. Assessment of covariates Demographic variables included age (continuous), sex (male or female), and race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, or other). Socioeconomic indicators comprised education level (less than high school, high school graduate, or college and above) and family poverty income ratio (PIR), calculated as the ratio of household income to the federal poverty threshold, and categorized as ≤ 1.0 (below poverty level), 1.1–3.0 (low to middle income), and > 3.0 (high income) [16]. Smoking status was defined as never, former, or current smoker based on lifetime cigarette use and current smoking behavior [17]. Drinking status was categorized as never, former, or current drinker according to self-reported alcohol consumption. Physical activity was grouped into three levels: inactive (no reported leisure-time activity), insufficiently active (engaging in moderate activity 1–5 times/week or vigorous activity 1–3 times/week), and active (more frequent moderate or vigorous activity), based on reported frequency and intensity [18, 19]. Diet quality was measured using the Healthy Eating Index (HEI), a score ranging from 0 to 100 that reflects adherence to the Dietary Guidelines for Americans [20]. The HEI was calculated from 24-hour dietary recall data and was categorized into quartiles, with higher quartiles indicating better diet quality. All covariates were assessed at baseline (the NHANES interview/examination) and were treated as baseline-only variables in the regression models. Statistical analyses All analyses accounted for the complex sampling design of NHANES by incorporating sampling weights, strata, and primary sampling units to ensure nationally representative estimates. Descriptive statistics were used to summarize baseline characteristics by CKM syndrome stages. Differences across groups were assessed using survey-weighted one-way ANOVA for normally distributed continuous variables, the Kruskal–Wallis test for non-normally distributed variables, and the Rao–Scott chi-square test for categorical variables. Kaplan–Meier curves with log-rank tests were used to compare cumulative mortality across CKM stages. Cox proportional hazards regression models were employed to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause, CCD, and cancer mortality. CKM syndrome was analyzed both as a five-level categorical variable (Stages 0–4) and as a binary variable (advanced CKM: Stages 3–4 vs. non-advanced CKM: Stages 0–2). Subgroup analyses were conducted to evaluate potential effect modification by demographic and lifestyle factors, with interaction tested on the multiplicative scale. Sensitivity analyses included excluding participants with missing covariate data and those who died within the first year of follow-up. All statistical analyses were performed using R software (version 4.3.1) with the “survey” packages. Two-sided P values < 0.05 were considered statistically significant. Results Study population characteristics Among the 2,598 cancer survivors included in the analysis, the mean age was 62.44 ± 0.39 years, and 59.3% were women (Table 1). The distribution of age and sex varied significantly across CKM syndrome stages, with older age and a higher proportion of men observed in more advanced stages. Sociodemographic and behavioral characteristics—including race/ethnicity, education level, PIR, smoking and drinking status—also differed across CKM stages (all P < 0.001), but no consistent trends were observed. Notably, the proportion of participants classified as physically inactive increased from 8.0% in Stage 0 to 42.5% in Stage 4. Diet quality, assessed by the Healthy Eating Index, did not differ significantly across stages. The median follow-up time was 7.9 (4.00–12.58) years. All-cause mortality increased substantially across CKM stages, from 7.2% in Stage 0 to 53.7% in Stage 4 (P < 0.001). Table 1Baseline characteristics of cancer survivors according to CKM syndrome stages—NHANES 1988–1994 and 1999–2018CharacteristicsaTotalAdults 20 years or older by cardiovascular-kidney-metabolic syndrome stagebP valuecStage 0Stage 1Stage 2Stage 3Stage 4No. of participants25981152461014699524Age, y62.44 ± 0.3947.74 ± 1.5853.53 ± 1.0758.15 ± 0.5376.87 ± 0.2669.79 ± 0.64< 0.001Sex, %< 0.001Women1397 (59.30)89 (80.12)178 (70.70)639 (63.59)272 (44.40)219 (48.07)Male1201 (40.70)26 (19.88)68 (29.30)375 (36.41)427 (55.60)305 (51.93)Race/ethnicity, %< 0.001Non-Hispanic white1895 (86.37)95 (94.42)161 (83.32)695 (86.99)552 (87.47)392 (82.41)Non-Hispanic black308 (5.39)7 (2.24)25 (3.68)136 (5.38)69 (5.41)71 (7.98)Mexican American189 (2.41)5 (0.58)25 (3.84)100 (2.81)34 (2.00)25 (1.44)Other206 (5.83)8 (2.75)35 (9.16)83 (4.82)44 (5.12)36 (8.18)Education level, %< 0.001Below high school705 (15.79)14 (9.39)34 (6.05)241 (13.13)223 (20.74)193 (27.24)High school657 (25.31)24 (13.30)70 (29.12)263 (24.16)178 (28.71)122 (26.40)Above high school1236 (58.90)77 (77.31)142 (64.83)510 (62.71)298 (50.55)209 (46.36)Family PIR, %< 0.001≤ 1.0364 (10.09)15 (12.12)25 (7.73)147 (9.11)79 (8.11)98 (16.11)1.1–3.01141 (35.23)42 (23.49)72 (19.66)403 (31.49)356 (47.68)268 (47.33)> 3.01093 (54.68)58 (64.39)149 (72.61)464 (59.40)264 (44.21)158 (36.57)Smoking status, %< 0.001Never smoker1169 (45.87)62 (54.41)127 (49.69)479 (47.62)305 (43.59)196 (37.37)Former smoker1039 (37.71)24 (19.57)77 (33.10)364 (34.70)331 (47.82)243 (44.81)Current smoker390 (16.42)29 (26.02)42 (17.21)171 (17.68)63 (8.59)85 (17.82)Drinking status, %< 0.001Never drinker380 (11.03)12 (7.69)25 (8.23)146 (9.63)115 (13.88)82 (15.01)Former drinker711 (20.82)19 (14.39)48 (13.34)246 (18.39)225 (27.04)173 (28.37)Current drinker1507 (68.15)84 (77.92)173 (78.43)622 (71.98)359 (59.08)269 (56.62)Physical activity, %< 0.001Inactive809 (27.37)15 (8.04)66 (26.82)245 (21.30)256 (35.58)227 (42.45)Insufficiently active938 (37.29)46 (36.42)89 (35.14)396 (40.79)241 (36.30)166 (30.91)Active851 (35.35)54 (55.54)91 (38.04)373 (37.92)202 (28.11)131 (26.64)Healthy eating index, %0.140> 69.3326 (12.97)16 (17.13)41 (15.80)105 (10.46)100 (16.25)64 (12.01)56.9–69.3635 (23.65)21 (17.31)52 (23.15)256 (23.62)181 (25.74)125 (24.19)< 56.91637 (63.38)78 (65.56)153 (61.05)653 (65.91)418 (58.01)335 (63.80)All-cause Mortality, %< 0.001No1433 (71.13)101 (92.80)197 (91.44)683 (79.87)269 (51.46)183 (46.30)Yes1165 (28.87)14 (7.20)49 (8.56)331 (20.13)430 (48.54)341 (53.70)Follow-up time, years7.92 (4.00,12.58)9.67 (5.67,14.75)7.92 (3.83,14.17)9.67 (5.33,14.58)5.75 (3.08, 9.75)5.67 (3.00, 9.25)< 0.001PIR, poverty income ratio; CKM, cardiovascular-kidney-metabolicaAll nonpregnant participants older than 20 years in the NHANES fasting subsample were includedbContinuous variables are described as means ± standard error (SE) or median (interquartile range, IQR). Categorical variables are presented as numbers (percentages). Sampling weights were applied for calculation of demographic descriptive statistics; N reflect the study sample while percentages reflect the survey-weighted datacContinuous variables were assessed using one-way ANOVA for normally distributed data and the Kruskal–Wallis test for non-normally distributed data. Categorical variables across CKM syndrome stages were compared using the Chi-square test Table 1Baseline characteristics of cancer survivors according to CKM syndrome stages—NHANES 1988–1994 and 1999–2018CharacteristicsaTotalAdults 20 years or older by cardiovascular-kidney-metabolic syndrome stagebP valuecStage 0Stage 1Stage 2Stage 3Stage 4No. of participants25981152461014699524Age, y62.44 ± 0.3947.74 ± 1.5853.53 ± 1.0758.15 ± 0.5376.87 ± 0.2669.79 ± 0.64< 0.001Sex, %< 0.001Women1397 (59.30)89 (80.12)178 (70.70)639 (63.59)272 (44.40)219 (48.07)Male1201 (40.70)26 (19.88)68 (29.30)375 (36.41)427 (55.60)305 (51.93)Race/ethnicity, %< 0.001Non-Hispanic white1895 (86.37)95 (94.42)161 (83.32)695 (86.99)552 (87.47)392 (82.41)Non-Hispanic black308 (5.39)7 (2.24)25 (3.68)136 (5.38)69 (5.41)71 (7.98)Mexican American189 (2.41)5 (0.58)25 (3.84)100 (2.81)34 (2.00)25 (1.44)Other206 (5.83)8 (2.75)35 (9.16)83 (4.82)44 (5.12)36 (8.18)Education level, %< 0.001Below high school705 (15.79)14 (9.39)34 (6.05)241 (13.13)223 (20.74)193 (27.24)High school657 (25.31)24 (13.30)70 (29.12)263 (24.16)178 (28.71)122 (26.40)Above high school1236 (58.90)77 (77.31)142 (64.83)510 (62.71)298 (50.55)209 (46.36)Family PIR, %< 0.001≤ 1.0364 (10.09)15 (12.12)25 (7.73)147 (9.11)79 (8.11)98 (16.11)1.1–3.01141 (35.23)42 (23.49)72 (19.66)403 (31.49)356 (47.68)268 (47.33)> 3.01093 (54.68)58 (64.39)149 (72.61)464 (59.40)264 (44.21)158 (36.57)Smoking status, %< 0.001Never smoker1169 (45.87)62 (54.41)127 (49.69)479 (47.62)305 (43.59)196 (37.37)Former smoker1039 (37.71)24 (19.57)77 (33.10)364 (34.70)331 (47.82)243 (44.81)Current smoker390 (16.42)29 (26.02)42 (17.21)171 (17.68)63 (8.59)85 (17.82)Drinking status, %< 0.001Never drinker380 (11.03)12 (7.69)25 (8.23)146 (9.63)115 (13.88)82 (15.01)Former drinker711 (20.82)19 (14.39)48 (13.34)246 (18.39)225 (27.04)173 (28.37)Current drinker1507 (68.15)84 (77.92)173 (78.43)622 (71.98)359 (59.08)269 (56.62)Physical activity, %< 0.001Inactive809 (27.37)15 (8.04)66 (26.82)245 (21.30)256 (35.58)227 (42.45)Insufficiently active938 (37.29)46 (36.42)89 (35.14)396 (40.79)241 (36.30)166 (30.91)Active851 (35.35)54 (55.54)91 (38.04)373 (37.92)202 (28.11)131 (26.64)Healthy eating index, %0.140> 69.3326 (12.97)16 (17.13)41 (15.80)105 (10.46)100 (16.25)64 (12.01)56.9–69.3635 (23.65)21 (17.31)52 (23.15)256 (23.62)181 (25.74)125 (24.19)< 56.91637 (63.38)78 (65.56)153 (61.05)653 (65.91)418 (58.01)335 (63.80)All-cause Mortality, %< 0.001No1433 (71.13)101 (92.80)197 (91.44)683 (79.87)269 (51.46)183 (46.30)Yes1165 (28.87)14 (7.20)49 (8.56)331 (20.13)430 (48.54)341 (53.70)Follow-up time, years7.92 (4.00,12.58)9.67 (5.67,14.75)7.92 (3.83,14.17)9.67 (5.33,14.58)5.75 (3.08, 9.75)5.67 (3.00, 9.25)< 0.001PIR, poverty income ratio; CKM, cardiovascular-kidney-metabolicaAll nonpregnant participants older than 20 years in the NHANES fasting subsample were includedbContinuous variables are described as means ± standard error (SE) or median (interquartile range, IQR). Categorical variables are presented as numbers (percentages). Sampling weights were applied for calculation of demographic descriptive statistics; N reflect the study sample while percentages reflect the survey-weighted datacContinuous variables were assessed using one-way ANOVA for normally distributed data and the Kruskal–Wallis test for non-normally distributed data. Categorical variables across CKM syndrome stages were compared using the Chi-square test Baseline characteristics of cancer survivors according to CKM syndrome stages—NHANES 1988–1994 and 1999–2018 PIR, poverty income ratio; CKM, cardiovascular-kidney-metabolic aAll nonpregnant participants older than 20 years in the NHANES fasting subsample were included bContinuous variables are described as means ± standard error (SE) or median (interquartile range, IQR). Categorical variables are presented as numbers (percentages). Sampling weights were applied for calculation of demographic descriptive statistics; N reflect the study sample while percentages reflect the survey-weighted data cContinuous variables were assessed using one-way ANOVA for normally distributed data and the Kruskal–Wallis test for non-normally distributed data. Categorical variables across CKM syndrome stages were compared using the Chi-square test Associations between CKM syndrome stages and mortality in cancer survivors During a median follow-up of 7.92 years (IQR: 4.00–12.58), there were 1165 all-cause deaths, 352 CCD deaths, and 350 cancer deaths. Kaplan–Meier curves showed a stepwise increase in mortality risk across CKM stages for all outcomes (log-rank P < 0.001; Fig. 2A–C). Mortality was highest among participants in Stages 3 and 4. When grouped into advanced (Stages 3–4) and non-advanced (Stages 0–2) CKM stages, individuals with advanced CKM had significantly higher cumulative incidence of all-cause, CCD, and cancer mortality (log-rank P < 0.001; Fig. 2D–F). Fig. 2Kaplan–Meier Curves for Mortality by CKM Syndrome Stage Among Cancer Survivors. Kaplan–Meier survival curves for all-cause (A), cardio-cerebrovascular disease (CCD) (B), and cancer mortality (C) across CKM syndrome stages (Stages 0 to 4). Panels D–F show cumulative mortality for all-cause (D), CCD (E), and cancer mortality (F) comparing participants with advanced CKM syndrome (Stages 3–4) versus non-advanced CKM syndrome (Stages 0–2). Log-rank P values for all comparisons < 0.001 Kaplan–Meier Curves for Mortality by CKM Syndrome Stage Among Cancer Survivors. Kaplan–Meier survival curves for all-cause (A), cardio-cerebrovascular disease (CCD) (B), and cancer mortality (C) across CKM syndrome stages (Stages 0 to 4). Panels D–F show cumulative mortality for all-cause (D), CCD (E), and cancer mortality (F) comparing participants with advanced CKM syndrome (Stages 3–4) versus non-advanced CKM syndrome (Stages 0–2). Log-rank P values for all comparisons < 0.001 In the fully adjusted model (Model 2), increasing CKM syndrome stage was associated with a stepwise elevation in the risk of all-cause and cause-specific mortality among cancer survivors (Table 2). Compared with participants in Stage 0, Stage 4 was associated with 3.48-fold higher all-cause mortality (HR = 3.48; 95% CI 2.62–4.63), 7.77-fold higher CCD mortality (HR = 7.77; 95% CI 4.21–14.32), and 2.55-fold higher cancer mortality (HR = 2.55; 95% CI 1.52–4.28). Estimates for intermediate stages (Stages 1–3) are presented in Table 2. When CKM stages were dichotomized, advanced CKM (Stages 3–4) was associated with higher hazards of all-cause death (HR = 1.83; 95% CI 1.63–2.05), CCD death (HR = 2.85; 95% CI 2.31–3.51), and cancer death (HR = 1.61; 95% CI 1.11–2.34) compared with non-advanced stages (Stages 0–2). Table 2Adjusted HRs (95% CIs) of all-cause and cause-specific mortality according to CKM syndrome stages among cancer survivorsa—NHANES 1988–1994 and 1999–2018CKM syndrome stagesP for trendeAdvanced CKM syndrome (Stages 3 or 4)P valueStage 0Stage 1Stage 2Stage 3Stage 4NoYes All-cause Mortality No. deaths/totalb14/11549/246331/1014430/699341/524394/1375771/1223Crude1 [Reference]1.63 (1.19–2.24)4.41 (3.42–5.69)40.73 (31.35–52.92)29.65 (22.77–38.62)< 0.0011 [Reference]10.84 (9.85–11.92)< 0.001Model 1c1 [Reference]1.18 (0.86–1.63)1.80 (1.37–2.36)3.13 (2.33–4.21)4.66 (3.51–6.18)< 0.0011 [Reference]2.27 (2.03–2.54)< 0.001Model 2d1 [Reference]1.15 (0.84–1.58)1.69 (1.29–2.21)2.44 (1.81–3.30)3.48 (2.62–4.63)< 0.0011 [Reference]1.83 (1.63–2.05)< 0.001 CCD Mortality No. deaths/totalb4/1158/24672/1014123/699145/52484/1375268/1223Crude1 [Reference]1.71 (0.84–3.51)6.28 (3.33–11.85)78.05 (41.22-147.77)74.96 (40.15-139.92)< 0.0011 [Reference]17.78 (15.09–20.94)< 0.001Model 1c1 [Reference]1.19 (0.61–2.32)2.33 (1.29–4.20)4.67 (2.40–9.08)9.83 (5.26–18.36)< 0.0011 [Reference]3.41 (2.77–4.20)< 0.001Model 2d1 [Reference]1.17 (0.60–2.28)2.21 (1.24–3.94)3.84 (2.00-7.37)7.77 (4.21–14.32)< 0.0011 [Reference]2.85 (2.31–3.51)< 0.001 Cancer Mortality No. deaths/totalb4/11520/246121/1014121/69984/524145/1375205/1223Crude1 [Reference]2.71 (1.58–4.67)5.67 (3.70–8.69)36.29 (23.25–56.64)22.12 (13.80-35.44)< 0.0011 [Reference]3.35 (2.52–4.44)< 0.001Model 1c1 [Reference]1.93 (1.10–3.39)2.26 (1.43–3.57)2.69 (1.59–4.55)3.29 (1.94–5.57)< 0.0011 [Reference]1.91 (1.30–2.80)< 0.001Model 2d1 [Reference]1.87 (1.08–3.23)2.16 (1.38–3.40)2.17 (1.28–3.68)2.55 (1.52–4.28)< 0.0011 [Reference]1.61 (1.11–2.34)0.007NHANES, National Health and Nutrition Examination Survey; CKM, cardiovascular-kidney-metabolic; CCD, cardio-cerebrovascular disease; PIR, poverty income ratio; HEI, healthy eating index; CKM, cardiovascular-kidney-metabolicaAll nonpregnant participants older than 20 years in the NHANES fasting subsample were includedbThe number of deaths and total number of participants in each category are unweightedcModel 1: Adjusted for age, sex, and race/ethnicitydModel 2: Model 1 + education level, family PIR, drinking status, smoking status, physical activity, and HEIeTests for linear trends across CKM syndrome stages were conducted by treating the stages as ordinal variables, assigned integer values from 0 to 4 Table 2Adjusted HRs (95% CIs) of all-cause and cause-specific mortality according to CKM syndrome stages among cancer survivorsa—NHANES 1988–1994 and 1999–2018CKM syndrome stagesP for trendeAdvanced CKM syndrome (Stages 3 or 4)P valueStage 0Stage 1Stage 2Stage 3Stage 4NoYes All-cause Mortality No. deaths/totalb14/11549/246331/1014430/699341/524394/1375771/1223Crude1 [Reference]1.63 (1.19–2.24)4.41 (3.42–5.69)40.73 (31.35–52.92)29.65 (22.77–38.62)< 0.0011 [Reference]10.84 (9.85–11.92)< 0.001Model 1c1 [Reference]1.18 (0.86–1.63)1.80 (1.37–2.36)3.13 (2.33–4.21)4.66 (3.51–6.18)< 0.0011 [Reference]2.27 (2.03–2.54)< 0.001Model 2d1 [Reference]1.15 (0.84–1.58)1.69 (1.29–2.21)2.44 (1.81–3.30)3.48 (2.62–4.63)< 0.0011 [Reference]1.83 (1.63–2.05)< 0.001 CCD Mortality No. deaths/totalb4/1158/24672/1014123/699145/52484/1375268/1223Crude1 [Reference]1.71 (0.84–3.51)6.28 (3.33–11.85)78.05 (41.22-147.77)74.96 (40.15-139.92)< 0.0011 [Reference]17.78 (15.09–20.94)< 0.001Model 1c1 [Reference]1.19 (0.61–2.32)2.33 (1.29–4.20)4.67 (2.40–9.08)9.83 (5.26–18.36)< 0.0011 [Reference]3.41 (2.77–4.20)< 0.001Model 2d1 [Reference]1.17 (0.60–2.28)2.21 (1.24–3.94)3.84 (2.00-7.37)7.77 (4.21–14.32)< 0.0011 [Reference]2.85 (2.31–3.51)< 0.001 Cancer Mortality No. deaths/totalb4/11520/246121/1014121/69984/524145/1375205/1223Crude1 [Reference]2.71 (1.58–4.67)5.67 (3.70–8.69)36.29 (23.25–56.64)22.12 (13.80-35.44)< 0.0011 [Reference]3.35 (2.52–4.44)< 0.001Model 1c1 [Reference]1.93 (1.10–3.39)2.26 (1.43–3.57)2.69 (1.59–4.55)3.29 (1.94–5.57)< 0.0011 [Reference]1.91 (1.30–2.80)< 0.001Model 2d1 [Reference]1.87 (1.08–3.23)2.16 (1.38–3.40)2.17 (1.28–3.68)2.55 (1.52–4.28)< 0.0011 [Reference]1.61 (1.11–2.34)0.007NHANES, National Health and Nutrition Examination Survey; CKM, cardiovascular-kidney-metabolic; CCD, cardio-cerebrovascular disease; PIR, poverty income ratio; HEI, healthy eating index; CKM, cardiovascular-kidney-metabolicaAll nonpregnant participants older than 20 years in the NHANES fasting subsample were includedbThe number of deaths and total number of participants in each category are unweightedcModel 1: Adjusted for age, sex, and race/ethnicitydModel 2: Model 1 + education level, family PIR, drinking status, smoking status, physical activity, and HEIeTests for linear trends across CKM syndrome stages were conducted by treating the stages as ordinal variables, assigned integer values from 0 to 4 Adjusted HRs (95% CIs) of all-cause and cause-specific mortality according to CKM syndrome stages among cancer survivorsa—NHANES 1988–1994 and 1999–2018 NHANES, National Health and Nutrition Examination Survey; CKM, cardiovascular-kidney-metabolic; CCD, cardio-cerebrovascular disease; PIR, poverty income ratio; HEI, healthy eating index; CKM, cardiovascular-kidney-metabolic aAll nonpregnant participants older than 20 years in the NHANES fasting subsample were included bThe number of deaths and total number of participants in each category are unweighted cModel 1: Adjusted for age, sex, and race/ethnicity dModel 2: Model 1 + education level, family PIR, drinking status, smoking status, physical activity, and HEI eTests for linear trends across CKM syndrome stages were conducted by treating the stages as ordinal variables, assigned integer values from 0 to 4 Stratified and sensitivity analyses In stratified analyses (Table S2), the association between advanced CKM syndrome and mortality was generally consistent across subgroups. However, significant interactions were observed for age. For all-cause mortality, the association was stronger among participants aged ≥ 60 years (HR = 3.93; 95% CI 1.91–8.07) compared to those < 60 years (HR = 2.45; 95% CI 2.00–2.98; P for interaction = 0.023). For cancer mortality, a significant interaction with age was also observed (P for interaction = 0.024), with a markedly higher risk in older adults (HR = 4.45; 95% CI 1.83–10.83) than in those younger than 60 years (HR = 1.37; 95% CI 0.99–1.89). No significant effect modification was found by sex, race/ethnicity, education, income, smoking, drinking, physical activity, or diet quality (all P for interaction > 0.05). Sensitivity analyses yielded similar results. After excluding participants with missing covariate data (n = 157; Table S3), advanced CKM syndrome remained significantly associated with increased risk of all-cause (HR = 1.62; 95% CI 1.29–2.03), CCD (HR = 2.92; 95% CI 1.92–4.47), and cancer mortality (HR = 1.61; 95% CI 1.10–2.36). Similarly, the exclusion of participants who died within the first year of follow-up (n = 53; Table S4) did not materially change the findings, indicating robustness of the associations. Advanced CKM remained significantly associated with all-cause (HR = 1.53; 95% CI 1.21–1.94), CCD (HR = 2.71; 95% CI 1.76–4.18), and cancer mortality (HR = 1.48; 95% CI 1.00–2.19). Discussion In this nationally representative cohort of 2598 U.S. cancer survivors, advanced CKM syndrome stages were independently associated with higher risks of all-cause, CCD, and cancer mortality over a median follow-up of approximately 8 years. A graded association was observed across CKM stages, and the highest risks were concentrated in Stage 4, highlighting the prognostic relevance of multi-organ cardiometabolic burden in survivorship. As cancer survival rates improve, long-term survivors increasingly face a growing burden of CKM syndrome [12]. Anticancer therapies, including chemotherapy, radiotherapy, immunotherapy, and targeted agents, can contribute to persistent metabolic dysregulation as well as cardiovascular and kidney injury, thereby promoting CKM progression over time [12]. In line with this concept, population-based evidence has shown higher CVD mortality among individuals with cancer than in the general population [21]. Lifestyle factors may further modify this risk: a large meta-analysis of cancer survivors reported lower all-cause mortality, cancer-specific mortality, and CVD incidence among those adhering to healthier lifestyle patterns, supporting the potential value of behavioral interventions during survivorship [22]. Kidney dysfunction is also an important contributor to adverse outcomes in cancer populations. Prior cohorts have reported that lower eGFR and CKD are independently associated with higher cancer-specific and all-cause mortality, and that these associations persist across cancer types [23, 24]. Metabolic abnormalities similarly appear to worsen cancer prognosis; meta-analyses have linked diabetes with higher mortality in ovarian cancer and across diverse malignancies [25, 26]. These findings were consistent with our observation that advanced stages of CKM syndrome were linked to increased cancer mortality among survivors. The coexistence of cardiovascular, renal, and metabolic dysfunction is frequently observed in cancer patients. This overlap stems in part from common underlying biological processes such as persistent inflammation, elevated oxidative stress, and disturbances in metabolic regulation [27]. Chronic inflammation in CKM syndrome is marked by elevated levels of pro-inflammatory cytokines such as interleukin-1β (IL-1β). These cytokines activate the nuclear factor kappa B (NF-κB) signaling pathway, which in turn promotes further cytokine production and endothelial activation [28]. In addition, pro-inflammatory cytokines contribute to endothelial dysfunction by increasing vascular permeability, enhancing the expression of adhesion molecules and reducing nitric oxide (NO) availability [29]. In cancer survivors, these processes may be further amplified by the long-term effects of chemotherapy, radiotherapy, and hormonal therapy, which can disrupt glucose and lipid metabolism, damage endothelial and renal tissues, and accelerate aging-related physiological decline. Cancer survivors represent a growing population with heightened vulnerability to CKM syndrome, reflecting both treatment-related toxicities and shared risk factors such as aging, physical inactivity, and adverse metabolic profiles. CKM syndrome has therefore become an important consideration in cardio-oncology, which addresses cardiovascular health across the cancer care continuum [30]. Anticancer therapies may precipitate or exacerbate cardiometabolic and renal dysfunction—particularly in individuals with pre-existing metabolic abnormalities—thereby amplifying CKM-related pathophysiology and contributing to excess morbidity and mortality [31]. Mechanistically, accumulating evidence supports a shared cardiometabolic basis for both cancer and CVD, including overlapping metabolic pathways and common modifiable risk factors [32, 33]. Although current CKM management is informed by cardiovascular, nephrology, and metabolic society recommendations, these frameworks were not developed specifically for cancer survivorship. As a result, they may not fully address the bidirectional interactions between oncologic therapies and CKM progression. These considerations underscore the need for survivorship-oriented strategies that integrate oncology with cardiology/cardio-oncology, nephrology, and metabolic care. A population-based study from Japan reported higher cardiovascular mortality among patients with cancer than in the general population and suggested that the excess risk may increase over time [34]. Cardiovascular complications in cancer survivors may reflect both acute treatment-related toxicity and longer-term cardiometabolic sequelae driven by persistent inflammation and oxidative stress, neuroendocrine dysregulation, immune perturbations, and cancer-associated hypercoagulability [35–37]. In addition, several widely used anticancer therapies (e.g., anthracyclines, tyrosine kinase inhibitors, and immune checkpoint inhibitors), as well as radiotherapy and major surgery, have been linked to cardiovascular adverse events [38–41]. Consistent with these observations, Stage 4 CKM syndrome in the present study was associated with substantially higher CCD mortality compared with Stage 0. Notably, the mortality risk associated with CKM syndrome was not limited to CCD-related causes. Cancer-specific mortality also increased significantly with CKM stage, which suggested that systemic metabolic and vascular dysfunction may negatively impact cancer progression, treatment response, or overall resilience. Furthermore, stratified analyses revealed that the associations were especially pronounced in older survivors (≥ 60 years), consistent with age-related vulnerability to multisystem decline and treatment toxicity. In a Japan study, senility emerged as the fourth most common cause of non-cancer-related death in cancer survivors, with a mortality risk approximately 5.5-fold higher than that of the general population [42]. Both aging and CKM syndrome appear to adversely impact the prognosis of cancer survivors. As cancer survivors are living longer, these age-related and systemic comorbidities may accelerate functional decline and contribute to increased mortality risk. To our knowledge, this is the first study to apply the 2023 AHA CKM framework to cancer survivors and demonstrate its relevance in predicting mortality outcomes across multiple domains. With a median follow-up of nearly 8 years, the study provided valuable insights into the association between CKM syndrome and long-term mortality outcomes among cancer survivors. From a clinical perspective, CKM staging may serve as a practical survivorship risk-stratification tool, as it can be derived from routinely collected measures and may help identify survivors who warrant intensified cardiometabolic prevention, closer monitoring, and timely referral to cardio-oncology/nephrology care. Despite substantial progress in managing cardiovascular, kidney, and metabolic diseases individually, existing clinical guidelines from cardiology, nephrology, and endocrinology societies do not fully capture the complexities of CKM syndrome in the context of cancer. These findings support incorporating CKM staging into survivorship pathways and multidisciplinary care models, enabling coordinated screening and management across oncology, cardiology/cardio-oncology, nephrology, endocrinology, nutrition, and rehabilitation. Such integration may help standardize the timing and intensity of cardiometabolic risk assessment, guide referral thresholds, and align preventive targets for high-risk survivors, particularly those with advanced CKM stages. Therefore, a tailored, multidisciplinary care model that accounts for the overlapping effects of cancer and CKM syndrome is urgently needed to improve long-term survivorship and quality of life. However, several limitations should be acknowledged. First, NHANES does not provide detailed cancer-related information (e.g., cancer type, stage at diagnosis, treatment modality, or recurrence), which precluded stratified analyses by cancer characteristics and limited our ability to account for heterogeneity in prognosis and treatment-related cardiometabolic effects. Second, due to the observational nature of the study, causality cannot be established, and residual confounding from unmeasured factors may persist. Third, the CKM staging algorithm required adaptation of the 2023 AHA CKM framework to the variables available in NHANES; despite using established thresholds where possible, these operational modifications may have introduced classification error (including potential stage misassignment). Fourth, cancer history in NHANES is self-reported rather than adjudicated, raising the possibility of misclassification of cancer survivor status. Additionally, lifestyle factors such as diet and exercise were self-reported, which can potentially introduce recall bias. Finally, the generalizability of our findings may be limited to U.S. populations and may not fully reflect outcomes in patients treated with more contemporary cancer therapies. Conclusion In this nationally representative cohort of U.S. cancer survivors, advanced CKM syndrome was significantly associated with increased risk of all-cause, cardio-cerebrovascular, and cancer mortality. These findings underscore the importance of early identification and comprehensive management of cardiometabolic and renal abnormalities in cancer survivorship care. Incorporating CKM risk stratification into routine clinical assessment may help improve long-term outcomes in this growing and vulnerable population. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1